Quoin Pharmaceuticals Expands Rare Disease Pipeline with New Clinical Study for Peeling Skin Syndrome
Quoin’s most advanced pipeline product, QRX003, also being evaluated to treat Netherton Syndrome
Recognizing that “rare diseases are only rare if you don’t live with one,” Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the planned initiation of an investigator-led clinical study in New Zealand to evaluate the safety and efficacy of QRX003 in a pediatric patient with Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment or cure. The clinical-stage specialty pharmaceutical company, is actively evaluating additional clinical sites in other countries with the aim of developing more products that treat rare and orphan diseases.
Michael Myers, CEO of Quoin Pharmaceuticals, stated, “We are excited to expand QRX003’s development into this second indication, Peeling Skin Syndrome. This planned initiation represents a key pillar of Quoin’s strategy to expand the clinical testing of QRX003 into other rare and orphan disease indications and we are actively assessing additional opportunities beyond this one.”
QRX003, Quoin’s most advanced pipeline product, is currently being evaluated in two late-stage clinical trials in the United States as a potential treatment for Netherton Syndrome (NS). With positive initial clinical data, these studies are being conducted under an open Investigational New Drug (IND) application with the Food and Drug Administration (FDA). Quoin is optimistic about receiving U.S. and EU approval in 2025 for NS, and is also exploring opportunities for advancing QRX003 into local Compassionate Use programs and other expedited approval pathways.
A unique “whole body, whole life” topical lotion, QRX003 targets NS hallmarks of skin inflammation and barrier disruption to support a more normalized rate of skin shedding. This could potentially result in the development of a more normally functioning skin barrier and a significant improvement in the quality of life for patients with NS, PSS and other conditions.
Quoin has established a global commercialization and distribution network encompassing 60-plus countries, with additional discussions underway to extend the commercial applicability of QRX003 and other products. The company’s strategic expansion efforts highlight its mission of addressing unmet medical needs and improving patient outcomes in rare and orphan diseases.
For more information about Quoin clinical trials, please visit: https://www.nethertonsyndromeclinicaltrials.com/
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
